论文部分内容阅读
胃癌是我国高发的恶性肿瘤之一,占全世界发病患者的40%左右,年发病在20/10万。目前就诊的胃癌患者大部分为中晚期,占70%以上,5年生存率在10%左右,患者死亡的主要原因为浸润及转移。对于晚期胃癌,目前主要应用化疗结合生物靶向治疗等手段。但胃癌对于化疗存在多药耐药,使得针对胃癌的治疗存在困难,缺乏有效的治疗手段。针对胃癌浸润转移及多药耐药的相关分子机制目前仍不甚明确。本文对Rho A与胃癌的相关研究进展展开一综述。
Gastric cancer is one of the high incidence of malignant tumors in our country, accounting for about 40% of the patients in the world, the annual incidence of 20/10 million. At present, the majority of gastric cancer patients are in the advanced stage, accounting for more than 70%, the 5-year survival rate is about 10%. The main cause of death is infiltration and metastasis. For advanced gastric cancer, the current main application of chemotherapy combined with biological targeting therapy and other means. However, gastric cancer has multi-drug resistance to chemotherapy, which makes it difficult to treat gastric cancer and lacks an effective treatment. The molecular mechanisms for invasion and metastasis of gastric cancer and multi-drug resistance are still not clear. This article reviews the progress of Rho A and gastric cancer.